Get started
Author

Aamir Saifuddin

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
2022 · James L Alexander, Nicholas A Kennedy, et al. · The Lancet. Gastroenterology & hepatology · 147
PDF
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
2022 · Simeng Lin, Nicholas A. Kennedy, et al. · Nature Communications · 105
PDF
COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine Dose
2022 · James L Alexander, Zhigang Liu, et al. · The Lancet. Gastroenterology & hepatology · 72
PDF
The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease
2022 · Christopher A. Lamb, Aamir Saifuddin, et al. · Gastroenterology · 71
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
2023 · James L. Alexander, Benjamin H. Mullish, et al. · EBioMedicine · 58
PDF
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
2021 · Shaji Sebastian, Gareth J Walker, et al. · The Lancet. Gastroenterology & hepatology · 38
PDF
Limitations of poster presentations reporting educational innovations at a major international medical education conference
2013 · Morris Gordon, Daniel Darbyshire, et al. · Medical Education Online · 17
PDF
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine
2022 · Zhigang Liu, James L. Alexander, et al. · Gastroenterology · 14
PDF
Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource
2025 · Christopher Roberts, Jaime Peters, et al. · Alimentary Pharmacology & Therapeutics · 12
PDF
Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study
2022 · Shaji Sebastian, Kamal V Patel, et al. · BMJ Open Gastroenterology · 11
PDF
Decoding cytokine networks in ulcerative colitis to identify pathogenic mechanisms and therapeutic targets
2026 · Marton Olbei, Isabelle Hautefort, et al. · Science Signaling · 10
PDF
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib
2023 · Zhigang Liu, James L Alexander, et al. · Journal of Crohn s and Colitis · 10
PDF
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
2023 · Zhigang Liu, James L. Alexander, et al. · EClinicalMedicine · 8
Tacrolimus therapy in moderate to subacute ulcerative proctocolitis: a large single-centre cohort study
2017 · Aamir Saifuddin, Adam Harris · Frontline Gastroenterology · 8
Towards excellence in cardiac surgery: experience from a developing country
2015 · Aamir Saifuddin, Syed Shahabuddin, et al. · International Journal for Quality in Health Care · 6
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID ‐19 pandemic: the PREPARE‐IBD multicentre cohort study
2022 · Aamir Saifuddin, Alexandra J. Kent, et al. · Alimentary Pharmacology & Therapeutics · 5
"Chase CRP", "Review patient": Improving the Quality of Weekend Medical Handover at a London Teaching Hospital
2015 · Aamir Saifuddin, Lucia Magee, et al. · BMJ Quality Improvement Reports · 4
PDF
DOP71 TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative Colitis
2023 · A Saifuddin, M Madgwick, et al. · Journal of Crohn s and Colitis · 2
PDF
OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients
2022 · S Lin, N A Kennedy, et al. · Journal of Crohn s and Colitis · 2
Improving the management of patients with acute red eyes in a large London Emergency Department
2014 · Aamir Saifuddin, Rachel Brookes · BMJ Quality Improvement Reports · 2
PDF
P0118 A novel subset of TNIP3+ OLR1+ AQP9+ inflammatory monocytes drives resistance to multiple biologics in ulcerative colitis
2025 · A Saifuddin, D Cozzetto, et al. · Journal of Crohn s and Colitis · 1
PDF
P279 Excessive accumulation of neutrophils in the epithelium, but not lamina propria, predicts resistance to ustekinumab in ulcerative colitis
2024 · A Saifuddin, N Powell · Journal of Crohn s and Colitis · 1
PDF
DOP62 A core molecular resistome characterised by extracellular matrix dysregulation and neutrophil degranulation predicts resistance to multiple therapies in Ulcerative Colitis
2024 · A Saifuddin, D Cozzetto, et al. · Journal of Crohn s and Colitis · 1
PDF
DOP31 Gene correlation network analyses reveal transcript modules and pathogenic mechanisms associated with resistance and response to ustekinumab therapy in Ulcerative Colitis
2024 · A Saifuddin, D Cozzetto, et al. · Journal of Crohn s and Colitis · 1
PDF
P75 Vaccine-induced antibody responses against influenza are diminished in infliximab and tofacitinib-treated IBD patients and correlate with responses to COVID-19 vaccination
2023 · James Alexander, Zhigang Liu, et al. · Gut · 1
Works count: 60
Citation count: 608
H-index: 10
I10-index: 12
Year
Topic
Type